Atlas Therapeutics Corporation (ATTH.OB) announced today that Dr. Louis Aronne has joined the company’s Board of Directors. A leading authority in the field of obesity research and treatment, Dr. Aronne has been involved in the field since 1986. He developed and is Director of the Comprehensive Weight Control Program, a multidisciplinary obesity research and treatment center. Dr. Aronne was also chairman of the development committee for the Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults, a joint publication of the National Institutes of Health, National Heart, Lung, and Blood Institute, and is a former President of the Obesity Society.

“I am very pleased and honored to join the Atlas Therapeutics board of directors. Obesity and diabetes are often associated with physical deconditioning and low muscle mass (sarcopenia). Weight loss is associated with a disproportionate reduction in muscle energy expenditure, the most likely cause of the plateau when our patients lose weight,” Dr. Aronne remarked. “I am excited by the potential which a novel product like MYO-T12(R) presents for improving sarcopenia, deconditioning, and the reduced energy expenditure of the plateau. I have great confidence in the team being put together to study and further develop this innovative product. We will soon put in place a development program which will highlight the unique metabolic potential of a product which works on muscle.”

Dr. Aronne advised the National Center for Health Promotion and Disease Prevention’s MOVE (Management of Overweight and Obese Veterans Everywhere) Program and has won several awards for teaching during his career including the Davidoff Prize from the Albert Einstein College of Medicine and the Eliot Hochstein Award from Weill-Cornell Medical College. He has authored or co-authored more than 50 papers and book chapters, including Weigh Less, Live Longer and the NY Times bestseller, The Skinny on Losing Weight Without Being Hungry.

Dr. Aronne graduated from the Johns Hopkins University School of Medicine and he currently serves as a Clinical Professor of Medicine at Weill Medical College of Cornell University, Adjunct Clinical Associate Professor of Medicine at Columbia University, and an Assistant Attending Physician at the New York Presbyterian Hospital/Weill Cornell Medical Center.

JB Bernstein, CEO of Atlas Therapeutics, commented, “Atlas Therapeutics is excited to welcome Dr. Aronne to our board. His expertise and pioneering nature in the field of obesity research and treatment will be a tremendous asset to the company. His counsel is welcomed as we roll out to market our revolutionary myostatin inhibitor, MYO-T12(R).”

Let us hear your thoughts below: